ERBB2 and neoplasm: Recently an ESR1 Y537N clone of CTC derived from a metastatic breast cancer patient with a TNBC, HER2-positive and estrogen receptor-positive (ER+) tumour was identified, which was characterized by the absence of mutations in the TP53 gene [37].